ES2630306T3 - Sistemas, métodos, y formulaciones para tratar el cáncer - Google Patents
Sistemas, métodos, y formulaciones para tratar el cáncer Download PDFInfo
- Publication number
- ES2630306T3 ES2630306T3 ES12806902.8T ES12806902T ES2630306T3 ES 2630306 T3 ES2630306 T3 ES 2630306T3 ES 12806902 T ES12806902 T ES 12806902T ES 2630306 T3 ES2630306 T3 ES 2630306T3
- Authority
- ES
- Spain
- Prior art keywords
- patients
- tumor
- cells
- hypoxia
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505393P | 2011-07-07 | 2011-07-07 | |
| US201161505393P | 2011-07-07 | ||
| US201161507950P | 2011-07-14 | 2011-07-14 | |
| US201161507950P | 2011-07-14 | ||
| PCT/US2012/045821 WO2013006821A1 (en) | 2011-07-07 | 2012-07-06 | Systems, methods, and formulations for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2630306T3 true ES2630306T3 (es) | 2017-08-21 |
Family
ID=47437478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12806902.8T Active ES2630306T3 (es) | 2011-07-07 | 2012-07-06 | Sistemas, métodos, y formulaciones para tratar el cáncer |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130011488A1 (enExample) |
| EP (2) | EP2729008B1 (enExample) |
| JP (3) | JP6082737B2 (enExample) |
| KR (2) | KR102020939B1 (enExample) |
| CN (2) | CN103796514A (enExample) |
| AU (2) | AU2012278813B2 (enExample) |
| CA (1) | CA2839727C (enExample) |
| ES (1) | ES2630306T3 (enExample) |
| IN (1) | IN2014DN00195A (enExample) |
| MX (1) | MX354383B (enExample) |
| PL (1) | PL2729008T3 (enExample) |
| RU (1) | RU2644635C2 (enExample) |
| WO (1) | WO2013006821A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
| EP2804857A1 (en) * | 2012-01-18 | 2014-11-26 | Concert Pharmaceuticals Inc. | Deuterated alpha-lipoic acid |
| CN103877066B (zh) * | 2014-02-21 | 2016-08-24 | 中国人民解放军第二军医大学 | 载多西他赛和莱菔硫烷的自组装纳米粒的制备方法与应用 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US11890292B2 (en) | 2017-02-27 | 2024-02-06 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| WO2018170457A1 (en) * | 2017-03-17 | 2018-09-20 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| ES3012841T3 (en) * | 2017-10-06 | 2025-04-10 | Res Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| WO2019099750A1 (en) | 2017-11-17 | 2019-05-23 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| WO2020061254A1 (en) * | 2018-09-19 | 2020-03-26 | Virginia Tech Intellectual Properties, Inc. | Brca1 modulating compounds, formulations thereof, and uses thereof |
| US20230008508A1 (en) * | 2019-12-10 | 2023-01-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapies for the treatment of cancer |
| CN112336716A (zh) * | 2020-11-25 | 2021-02-09 | 四川大学华西医院 | 维生素c和双硫仑在制备抗肿瘤联合用药物中的用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4569836A (en) * | 1981-08-27 | 1986-02-11 | Gordon Robert T | Cancer treatment by intracellular hyperthermia |
| JP2514500B2 (ja) * | 1991-09-14 | 1996-07-10 | 呉羽化学工業株式会社 | 多剤耐性抑制剤及び発現阻害剤 |
| DE69719320T2 (de) * | 1996-06-11 | 2003-12-11 | Novartis Ag, Basel | Kombination eines somatostatin analogs und eines rapamycins |
| US5865722A (en) | 1997-04-04 | 1999-02-02 | Numotech, Incorporated | Shape-adaptable topical hyperbaric oxygen chamber |
| US6299925B1 (en) * | 1999-06-29 | 2001-10-09 | Xel Herbaceuticals, Inc. | Effervescent green tea extract formulation |
| US6376525B1 (en) * | 2000-09-15 | 2002-04-23 | Qingzhong Kong | Method and composition for treating cancer using cellular organelle crystallizing agents |
| EP1355566B1 (en) * | 2000-12-18 | 2012-11-28 | Board Of Regents, The University Of Texas System | Local regional chemotherapy and radiotherapy using in situ hydrogel |
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| US7435725B2 (en) * | 2001-11-06 | 2008-10-14 | The Quigly Corporation | Oral compositions and methods for prevention, reduction and treatment of radiation injury |
| US20030105104A1 (en) * | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US6572897B1 (en) * | 2002-07-03 | 2003-06-03 | Vitacost.Com, Inc. | Insulin sensitivity maintenance and blood sugar level maintenance formulation for the prevention and treatment of diabetes |
| CA2535889A1 (en) * | 2003-08-29 | 2005-03-17 | Aton Pharma, Inc. | Combination methods of treating cancer |
| EP1571225A1 (en) * | 2004-03-02 | 2005-09-07 | PrimaGen Holding B.V. | Diagnosis of a disease and monitoring of therapy using the AC133 gene |
| US20060045912A1 (en) * | 2004-08-30 | 2006-03-02 | Peter Truog | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| JP2006298781A (ja) * | 2005-04-15 | 2006-11-02 | Geno Membrane:Kk | エストロン３硫酸トランスポーター活性阻害剤 |
| CA2647986C (en) * | 2006-03-31 | 2014-07-08 | Erasmus University Medical Center Rotterdam | Compositions for tumor growth control |
| EP1847274A1 (en) * | 2006-04-21 | 2007-10-24 | CIPROSA LLC - Corporate Creations Network, Inc. | Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy |
| WO2008011363A2 (en) * | 2006-07-17 | 2008-01-24 | Thomas Christian Lines | Quercetin-containing compositions |
| CA2674084C (en) * | 2006-12-26 | 2013-05-14 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| US20080305096A1 (en) * | 2007-06-07 | 2008-12-11 | Unicity International, Inc. | Method and composition for providing controlled delivery of biologically active substances |
| WO2009046377A2 (en) * | 2007-10-04 | 2009-04-09 | Medistem Laboratories, Inc. | Compositions and methods of stem cell therapy for autism |
| CA2716321A1 (en) * | 2008-02-21 | 2009-08-27 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
| MX2011000719A (es) * | 2008-07-18 | 2011-03-01 | Novartis Ag | Uso de inhibidores de desacetilasa de histona (hdac) para el tratamiento de enfermedad de hodgkin. |
| US20100316733A1 (en) * | 2009-06-15 | 2010-12-16 | Locklear Kenneth R | Hyperbaric Oxygen Therapy and Treatment Method |
-
2012
- 2012-07-06 JP JP2014519082A patent/JP6082737B2/ja active Active
- 2012-07-06 US US13/543,563 patent/US20130011488A1/en not_active Abandoned
- 2012-07-06 MX MX2014000150A patent/MX354383B/es active IP Right Grant
- 2012-07-06 PL PL12806902T patent/PL2729008T3/pl unknown
- 2012-07-06 CN CN201280033815.9A patent/CN103796514A/zh active Pending
- 2012-07-06 CA CA2839727A patent/CA2839727C/en active Active
- 2012-07-06 EP EP12806902.8A patent/EP2729008B1/en active Active
- 2012-07-06 EP EP17163492.6A patent/EP3326625A1/en not_active Withdrawn
- 2012-07-06 ES ES12806902.8T patent/ES2630306T3/es active Active
- 2012-07-06 KR KR1020147003161A patent/KR102020939B1/ko active Active
- 2012-07-06 KR KR1020197026111A patent/KR20190107166A/ko not_active Withdrawn
- 2012-07-06 WO PCT/US2012/045821 patent/WO2013006821A1/en not_active Ceased
- 2012-07-06 CN CN201910036937.7A patent/CN109675041A/zh active Pending
- 2012-07-06 AU AU2012278813A patent/AU2012278813B2/en active Active
- 2012-07-06 RU RU2014101261A patent/RU2644635C2/ru active
-
2014
- 2014-01-09 IN IN195DEN2014 patent/IN2014DN00195A/en unknown
-
2016
- 2016-03-21 US US15/076,371 patent/US20170014376A1/en not_active Abandoned
- 2016-12-08 AU AU2016269491A patent/AU2016269491B2/en active Active
-
2017
- 2017-01-23 JP JP2017009055A patent/JP6401317B2/ja active Active
-
2018
- 2018-09-06 JP JP2018166950A patent/JP2018203767A/ja active Pending
-
2019
- 2019-02-05 US US16/268,279 patent/US20200206183A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014518274A (ja) | 2014-07-28 |
| US20200206183A1 (en) | 2020-07-02 |
| JP2017105797A (ja) | 2017-06-15 |
| AU2016269491A1 (en) | 2017-01-05 |
| KR20190107166A (ko) | 2019-09-18 |
| MX354383B (es) | 2018-03-02 |
| RU2014101261A (ru) | 2015-08-20 |
| EP3326625A1 (en) | 2018-05-30 |
| WO2013006821A1 (en) | 2013-01-10 |
| CN109675041A (zh) | 2019-04-26 |
| JP2018203767A (ja) | 2018-12-27 |
| CN103796514A (zh) | 2014-05-14 |
| CA2839727C (en) | 2023-10-17 |
| JP6082737B2 (ja) | 2017-02-15 |
| RU2644635C2 (ru) | 2018-02-13 |
| MX2014000150A (es) | 2014-05-14 |
| AU2012278813B2 (en) | 2016-09-08 |
| EP2729008A1 (en) | 2014-05-14 |
| PL2729008T3 (pl) | 2017-10-31 |
| US20130011488A1 (en) | 2013-01-10 |
| EP2729008B1 (en) | 2017-04-05 |
| EP2729008A4 (en) | 2014-10-29 |
| AU2012278813A1 (en) | 2014-01-30 |
| JP6401317B2 (ja) | 2018-10-10 |
| CA2839727A1 (en) | 2013-01-10 |
| US20170014376A1 (en) | 2017-01-19 |
| IN2014DN00195A (enExample) | 2015-06-05 |
| KR20140076546A (ko) | 2014-06-20 |
| AU2016269491B2 (en) | 2018-08-30 |
| KR102020939B1 (ko) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2630306T3 (es) | Sistemas, métodos, y formulaciones para tratar el cáncer | |
| ES2791539T3 (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresión de DUX4 | |
| HUE032389T2 (en) | Preparations and methods for treating cancer | |
| Zhu et al. | Quercetin mitigates radiation-induced intestinal injury and promotes intestinal regeneration via Nrf2-mediated antioxidant pathway1 | |
| Zhu et al. | Thyroxine affects lipopolysaccharide‐induced macrophage differentiation and myocardial cell apoptosis via the NF‐κB p65 pathway both in vitro and in vivo | |
| BR112020003349A2 (pt) | composições e métodos para modular o crescimento capilar | |
| ES2922284T3 (es) | Uso de una dieta que simula el ayuno para mejorar la eficacia de los antiestrógenos en terapia contra el cáncer | |
| ES2358931T3 (es) | Uso de un inhibidor de quinasa p38 para el tratamiento de trastornos psiquiatricos. | |
| ES3054693T3 (en) | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder | |
| WO2022271731A1 (en) | Wee1 inhibitors and methods for treating cancer | |
| Wang et al. | Saikosaponin A alleviates rat liver fibrosis by inhibiting Hedgehog signaling pathway-mediated autophagy and NLRP3 inflammasome | |
| CN104622874B (zh) | Ccr4拮抗剂在抑制癌生长及转移中的应用 | |
| CN101448514A (zh) | 黑素瘤的治疗 | |
| JP2007505859A (ja) | イマチニブおよびミドスタウリンでの消化管間質腫瘍の処置 | |
| CN111195250A (zh) | 西达本胺联合dice的应用及联合药物 | |
| US20200009085A1 (en) | Methods For Treating Ovarian Cancer | |
| Grover et al. | Melatonin: Linking Periodontal Disease and Systemic Health | |
| CA3218103A1 (en) | Autotaxin (atx) inhibitor for the treatment of pancreatic cancer | |
| JP2024508644A (ja) | 老化関連分泌表現型を下方制御する抗老化植物ポリフェノール薬およびその使用 | |
| CN102526012A (zh) | 视黄酸及其衍生物在制备治疗肝纤维化药物中的应用 | |
| WO2008031358A1 (fr) | 1,2-dihydroxy-3-methyl-9,10-anthraquinone utile dans la fabrication de médicaments pour traiter les cancers | |
| BR112019013371A2 (pt) | novos derivados de fenila | |
| JP2006206543A (ja) | 抗癌剤、癌細胞の増殖を抑制する方法 | |
| BR122024017981A2 (pt) | Composição, forma de dosagem, produto e usos de niraparibe no tratamento de câncer de próstata | |
| HK40004751A (en) | Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof |